StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note released on Monday morning. The firm issued a sell rating on the biotechnology company’s stock.
Cellectis Stock Down 0.5 %
Shares of CLLS opened at $1.82 on Monday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.92 and a current ratio of 1.92. The company has a 50-day simple moving average of $2.13 and a 200-day simple moving average of $2.30. Cellectis has a 52 week low of $0.96 and a 52 week high of $3.77. The firm has a market capitalization of $101.16 million, a P/E ratio of -1.41 and a beta of 3.09.
Cellectis (NASDAQ:CLLS – Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.05. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. The firm had revenue of $9.50 million during the quarter, compared to analysts’ expectations of $6.00 million. On average, equities research analysts expect that Cellectis will post -0.54 earnings per share for the current year.
Institutional Investors Weigh In On Cellectis
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Further Reading
- Five stocks we like better than Cellectis
- Stock Analyst Ratings and Canadian Analyst Ratings
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- The Most Important Warren Buffett Stock for Investors: His Own
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- How to Calculate Options Profits
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.